Overview

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus. The extension study was an extension to double-blind study of 16 weeks (TA-7284-11)
Phase:
Phase 4
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Canagliflozin
Insulin
Insulin, Globin Zinc